Kobiolabs Inc. (348150) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kobiolabs Inc. (348150:KRX), powered by AI.
- Current Price
- ₩5,460
- P/E Ratio
- -19.8
- Market Cap
- 105.2B
- Sector
- Healthcare
What is the Kobiolabs Inc. stock price forecast?
Kobiolabs Inc. is currently trading at ₩5,460. View real-time AI analysis on Alpha Lenz.
What is Kobiolabs Inc. insider trading activity?
View the latest insider trading data for Kobiolabs Inc. on Alpha Lenz.
What is Kobiolabs Inc.'s P/E ratio?
Kobiolabs Inc.'s P/E ratio is -19.8.
Kobiolabs Inc.
“Kobiolabs Inc. trades at a P/E of -19.8 (undervalued) with modest ROE of -12.8%. 3Y revenue CAGR of 186.9% highlights clear growth momentum.”
Ask for details →Company Overview
Kobiolabs Inc. is a biotechnology company that specializes in developing innovative therapies and solutions aimed at addressing critical medical challenges. The company's primary function is to research and advance biopharmaceutical products that target unmet needs in the healthcare industry, focusing on areas such as oncology, rare genetic disorders, and autoimmune diseases. Kobiolabs Inc. is actively engaged in numerous clinical trials, collaborating with medical institutions and research organizations to push the boundaries of modern medicine. The significance of Kobiolabs in the market is underscored by its commitment to transforming scientific discovery into tangible health benefits, thereby contributing to the biotech sector's role in enhancing public health. Through its focus on cutting-edge research and development, Kobiolabs plays a pivotal role in the biotech industry, influencing trends and driving innovation in healthcare solutions.
Company Statistics
(FY 2024)Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Kobiolabs Inc. trades at a P/E of -19.8 (undervalued) with modest ROE of -12.8%. 3Y revenue CAGR of 186.9% highlights clear growth momentum.”
Ask for details →